INDEMNITY AGREEMENTIndemnification Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, 20__, is made by and between ArTara Therapeutics, Inc., a Delaware corporation (the “Company”), and _________________ (“Indemnitee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between ArTara Therapeutics, Inc. (the “Company”), and Jesse Shefferman (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreement and Plan of Merger and Reorganization • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made and entered into as of November 19, 2019, by and among PROTEON THERAPEUTICS, INC., a Delaware corporation (“Parent”), REM 1 ACQUISITION, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Proteon Merger Sub”), and ARTARA THERAPEUTICS, INC., a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
SUBSCRIPTION AGREEMENTSubscription Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Subscription Agreement (this “Agreement”) is made and entered into as of September 23, 2019 (the “Effective Date”) by and among Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 11 hereof.
CHOLINE LICENSE AGREEMENTCholine License Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Virginia
At the end of the calendar quarter in which the U.S. Orphan Drug Designation expires, then the royalty rate applicable to all Net Sales, irrespective of geography shall be […***…] percent ([…***…]%) of Net Sales.
SPONSORED RESEARCH AND LICENSE AGREEMENTSponsored Research and License Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Iowa
This Sponsored Research and License Agreement (this “Agreement”) is entered into on November 28, 2018 (the “Effective Date”), by and between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (“ArTara”), and The University of Iowa, located at c/o Division of Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (“University”). ArTara and University may individually be referred to herein as a “Party,” and collectively as “Parties.”
AgreementConfidentiality Agreement • January 10th, 2020 • ArTara Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Agreement (this “Agreement”), dated and effective as of June 17th, 2019 (the “Effective Date”), is entered into by and between CHUGAI PHARMACEUTICAL CO., LTD., a company organized and existing under the laws of Japan, having its principal office at 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo 103-8324, Japan (“Chugai”) and ARTARA THERAPEUTICS INC., a corporation organized under the laws of the state of Delaware, U.S.A., having its principal office at 1 Little West 12th Street, New York, NY 10014 (“ArTara”) (collectively, the “Parties,” or each, individually, a “Party”).
